There’s an increasing focus on using drugs to modify the tumour microenvironment, reducing immunosuppression and breaking down the barrier of fibrotic scar tissue that blocks many therapies. Optimum Strategic Communications’ Richard Staines talked to our client iOnctura, about the Company’s plans to use an autotaxin inhibitor to remove this obstacle. Scientists are looking at a […]
No-one is likely to forget the tragic events of 2020 and one company leading efforts to prepare for the next pandemic is Poolbeg Pharma. Optimum Strategic Communications’ Richard Staines interviewed CEO Jeremy Skillington to find the latest insights. Discussions are not about whether another pandemic will happen, but when, as a number of factors converge […]
A much-anticipated new potential drug for COPD moved a step closer to the market after Verona Pharma submitted its New Drug Application to the U.S. FDA, seeking approval of ensifentrine as a maintenance therapy. In the latest episode of Optimum Perspectives podcast, Eva Haas caught up with Chris Martin, Senior Vice President of Commercial, who […]
Is a world without disease possible? That was the question posed by a meeting held at The Royal Society of Medicine in London last month. I hate to be a killjoy – but the answer is ‘No’. A world without disease would be a world without death. I’m sure the organisers of the The World […]
One Nucleus’ On Helix Conference 2023, provided insight into the current climate for Biotech companies, including the international outlook, and what to expect in the future. The past few years have been tough for the international Biotech market, with funding, Brexit, new regulations, trade agreements and supply chain issues. Additionally, valuations have fallen and consequently […]
